Clinical Trial Update: Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Flutemetamol (18F) injection as a prognostic imaging agent to identify amnestic mild cognitive impairment patients who will convert to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Flutemetamol (18F) injection (flutemetamol)

Snippet

Sponsor: GE Healthcare | Conditions: Mild Cognitive Impairment, Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-09-11